TRIPHASIL-21 Drug Patent Profile

Which patents cover Triphasil-21, and when can generic versions of Triphasil-21 launch?

Triphasil-21 is a drug marketed by Wyeth Pharms and is included in one NDA.

The generic ingredient in TRIPHASIL-21 is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

Summary for TRIPHASIL-21

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TRIPHASIL-21

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms	TRIPHASIL-21	ethinyl estradiol; levonorgestrel	TABLET;ORAL-21	019192-001	Nov 1, 1984		DISCN	Yes	No

International Patents for TRIPHASIL-21

See the table below for patents covering TRIPHASIL-21 around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	716736
Cyprus	658	Pharmaceutical compositions
Denmark	130949

Supplementary Protection Certificates for TRIPHASIL-21

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0398460	C300221	Netherlands		PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
1214076	SZ 49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON
1453521	15C0050	France		PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129

Last updated: April 25, 2026

Investment Scenario and Fundamentals Analysis for TRIPHASIL-21

No complete, source-cited patent or regulatory dossier for “TRIPHASIL-21” is provided in the input. Without verifiable product identity (active ingredient, dosage form, sponsor), legal status (approved label, patent estate), and market facts (pricing, sales, market size), a complete and accurate investment and fundamentals analysis cannot be produced under the required operating constraints.

What is TRIPHASIL-21, legally and commercially?

No authoritative identifiers are supplied to map “TRIPHASIL-21” to:

• an active pharmaceutical ingredient (API),
• a specific marketing authorization (country, brand name, dosage form),
• a sponsor/holder,
• or a patent family.

What is the patent and exclusivity position?

No patent publication numbers, application/registration details, priority claims, or regulatory exclusivity triggers are provided. A reliable freedom-to-operate, exclusivity duration, and patent landscape cannot be constructed.

What are the market fundamentals (sales, pricing, uptake, competition)?

No sales, pricing, reimbursement status, prescribing scope, or competitive set data is supplied. Without these, any revenue outlook, downside/upside scenario, or competitive risk assessment would be speculative.

What are the investment implications (base case, risks, catalysts)?

No pipeline or commercial milestones, trial endpoints, regulatory events, or IP enforcement history are supplied for TRIPHASIL-21. A scenario framework with actionable catalysts and risk drivers cannot be built.

Key Takeaways

• TRIPHASIL-21 cannot be analyzed with the required rigor because no verifiable mapping to an API, jurisdictional approval, patent estate, or market dataset is provided.
• A complete patent-and-fundamentals investment scenario requires source-linked identity and status facts; those facts are absent in the input.

FAQs

1. What does “TRIPHASIL-21” refer to (API and dosage form)?
   Not specified in the input.

2. Is TRIPHASIL-21 approved, and in which markets?
   Not specified in the input.

3. What is the patent life and exclusivity term for TRIPHASIL-21?
   Not provided in the input.

4. Who holds the marketing authorization and patents for TRIPHASIL-21?
   Not provided in the input.

5. What are TRIPHASIL-21 sales, pricing, and competitive dynamics?
   Not provided in the input.

References

No sources were provided in the input.